Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 10/20 | 0.48 |
| ▸ | TACR3 | P29371 | 13/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | DHODH | Q02127 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5414261 | 0.94 | TACR2 (0.47) | TACR2TACR3KCNH2OPRM1PDE10A | |
| SCHEMBL5908771 | 0.91 | TACR3 (0.50) | TACR2TACR3KCNH2OPRM1PDE10A | |
| SCHEMBL5438840 | 0.91 | TACR2 (0.48) | TACR2TACR3KCNH2OPRM1PDE10A | |
| SCHEMBL5418589 | 0.91 | TACR2 (0.47) | TACR2TACR3KCNH2OPRM1PDE10A | |
| SCHEMBL5451916 | 0.90 | TACR3 (0.49) | TACR2TACR3KCNH2OPRM1PDE10A | |
| SCHEMBL5908871 | 0.89 | TACR3 (0.51) | TACR2TACR3KCNH2OPRM1 | |
| SCHEMBL5424841 | 0.89 | TACR3 (0.52) | TACR2TACR3KCNH2OPRM1PDE10A | |
| SCHEMBL5445446 | 0.89 | TACR2 (0.52) | TACR2TACR3KCNH2OPRM1PDE10A | |
| SCHEMBL5422409 | 0.89 | DHODH (0.53) | PDE10ADHODH | |
| SCHEMBL5447132 | 0.88 | TACR3 (0.48) | TACR2TACR3KCNH2OPRM1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060223819-A1 | Quinoline Derivatives as NK-3 Antagonists | GlaxoSmithKline S.P.A. & Laboratoire | 2006-10-05 | — | — | US | disclosed |
| US-20040097518-A1 | Quinoline derivatives as nk-3 antagonists | GLAXOSMITHKLINE S.P.A. (IT) | 2004-05-20 | — | — | US | disclosed |
| EP-1351953-A1 | QUINOLINE DERIVATIVES AS NK-3 ANTAGONISTS | GlaxoSmithKline S.p.A. (IT) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002044165-A1 | QUINOLINE DERIVATIVES AS NK-3 ANTAGONISTS | GLAXOSMITHKLINE SPA (IT) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223819-A1 | Quinoline Derivatives as NK-3 Antagonists | KCNK3, KCNQ3, KCNN3 | TACR2 83/4885TACR3 50/4885KCNH2 22/4885 |
| US-20040097518-A1 | Quinoline derivatives as nk-3 antagonists | KCNK3, KCNQ3, KCNN3 | TACR2 83/4885TACR3 53/4885KCNH2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.